VOYAGER
Avapritinib failed to beat regorafenib in unselected later-line GIST, confining it to the PDGFRA D842V niche.
PFS 4.2 vs 5.6 months (HR 1.25); ORR 17% vs 7%. Avapritinib's GIST label remains limited to PDGFRA exon 18 mutations.
Setting
Third/fourth-line GIST: avapritinib vs regorafenib
Phase
Phase 3
Sponsor
Blueprint Medicines
Registry
Headline result
PFS HR 1.25 (negative).
Reported
2020
Enrolled
476
In plain words
What these results mean for people, not percentages
Progression-free survival (median)primarysurrogate endpoint
- Median 4.2 vs 5.6 months with Avapritinib compared with Regorafenib; about 1.4 months shorter for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 25 percent higher chance of the event at any given time (hazard ratio 1.25, likely range 0.99 to 1.57).
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Third/fourth-line GIST: avapritinib vs regorafenib. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.